📋 Indications & Clinical Dosage
*To rhesus-negative woman for prevention of Rh0 (D) sensitisation, following birth of rhesus-positive infant, OR following any potentially sensitizing episode (e.g. stillbirth, abortion, amniocentesis) 20-28 weeks gestation:*
BY DEEP IM INJ: Females of childbearing potential: 1 vial to be administered immediately or within 72 hours of childbirth; for transplacental bleed of over 4ml fetal red cells, extra100-125 units per ml fetal red cells, subcutaneous route used for patients with bleeding disorders.
BY IV INJ: Lyophilized incomplete anti-D sera with negative 1 gm-Anti-D at least 300 mcg: Females: within 84 hr of every termination of pregnancy, abortion or delivery to Rh-negative women with Rh-positive baby. The adjustment of dose can be made as 1 amp of Anti Rh0 300 for every 30-50 ml, transfused blood. For Rh-negative female infant of Rh-positive mothers, one third of adult dose just after delivery.
*To rhesus-negative woman for prevention of Rh0 (D)
sensitisation, antenatal prophylaxis:*
BY DEEP IM INJ: Females of childbearing potential: 1vial to begiven at weeks 28 and 34 of pregnancy, if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, subcutaneous route used for patients with bleeding disorders.
⛔ Contraindications
Treatment of idiopathic thrombocytopenia purpura in rhesus negative patients, treatment of idiopathic thrombocytopenia purpura in splenectomised patients
⚠️ Precautions & Warnings
Immunoglobulin A deficiency, possible interference with live virus vaccines. Should be given with caution with a history of prior systemic allergic reactions following the administration of human im-munoglobulin preparations; physician must weigh the benefits of immunization against the potential risks of hypersensitivity reaction
🔄 Drug Interactions
May interfere with the live vaccines to induce an immune response and a suitable interval shduld separate their administration.
⚠️ Adverse Reactions / Side Effects
Anaphylaxis, abdominal pain, arthralgia, asthenia, back pain, diarrhoea, dizziness, drowsiness, fever, headache, hypertension, hypotension, injection site pain,malaise, myalgia, nausea, pruritus, rash, sweating, vomiting, dyspnea, hypotension, tachycardia, urticaria
📚 Official Regulatory & Clinical References
- Drug Regulatory Authority of Pakistan (DRAP): Drug Registration, S.R.O. Price Gazettes & National Essential Medicines List (NEML).
- World Health Organization (WHO): Collaborating Centre for Drug Statistics Methodology (ATC/DDD Index).
- Formulary Standards: British National Formulary (BNF) & Pakistan National Formulary (PNF) guidelines.